National Lung Cancer Audit Report 2018: where are we for lung cancer care in the UK?
Real world analysis of second-line osimertinib use for NSCLC in North West London
Meeting the recommended mediastinal staging standards for endosonography in everyday practice
Immunotoxicity in advanced lung cancer: how does this influence future practice?
More evidence needed to support checkpoint inhibitor use in late-stage cancer